Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Nanoplatforms Based Cancers Therapy
share announcement

Nanoplatforms Based Cancers Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: closed (30 May 2022) | Viewed by 17590

Special Issue Editor

Dr. Magali Gary-Bobo

E-Mail Website
Guest Editor
IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France
Interests: photodynamic therapy; two-photon excitation; cancer targeting
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanomedicine is now considered a hopeful strategy with which to target efficiently cancer cells and deliver, more specifically, the molecule of interest to the area to imaging and treatment. A large variety of biocompatible nanoparticles has been produced in the last few years to carry and protect from biological barriers, molecules designed for imaging or therapy. In addition, grafting with targeting moieties allows better addressing of the tumor area. Finally, a stimuli response system such as laser, temperature or ultrasounds, to deliver the cargo at the site selected, can bring a supplementary dimension for the conception of high potency controlled nanodevices.

In this Special Issue, we will focus on novel nanoplatforms for the therapy and/or imaging of cancers. The therapeutic strategy could be drug or nucleic acid delivery, photodynamic or photothermal or ultrasounds therapy; in addition, surface ligands anchoring could be a strong advantage to efficiently address the nanoplatforms to tumor area and, more particularly, to cancer cells. This Special Issue aims to highlight novel nanodevices with cancer applications.

Dr. Magali Gary-Bobo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoplatforms
  • cancer therapy
  • imaging
  • targeting
  • controlled delivery

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2509 KiB  
Article
Lipid-Nanoparticle-Mediated Delivery of Docetaxel Prodrug for Exploiting Full Potential of Gold Nanoparticles in the Treatment of Pancreatic Cancer
by Abdulaziz Alhussan, Nolan Jackson, Sarah Eaton, Nancy Dos Santos, Ingrid Barta, Josh Zaifman, Sam Chen, Yuen Yi C. Tam, Sunil Krishnan and Devika B. Chithrani
Cancers 2022, 14(24), 6137; https://doi.org/10.3390/cancers14246137 - 13 Dec 2022
Cited by 7 | Viewed by 2249
Abstract
Current chemoradiation therapy suffers from normal tissue toxicity. Thus, we are proposing incorporating gold nanoparticles (GNPs) and docetaxel (DTX), as they have shown very promising synergetic radiosensitization effects. Here, we explored the effect of a DTX prodrug encapsulated in lipid nanoparticles (LNPDTX-P [...] Read more.
Current chemoradiation therapy suffers from normal tissue toxicity. Thus, we are proposing incorporating gold nanoparticles (GNPs) and docetaxel (DTX), as they have shown very promising synergetic radiosensitization effects. Here, we explored the effect of a DTX prodrug encapsulated in lipid nanoparticles (LNPDTX-P) on GNP uptake in pancreatic cancer models in vitro and in vivo. For the in vitro experiment, a pancreatic cancer cell line, MIA PaCa-2, was cultured and dosed with 1 nM GNPs and 45 nM free DTX or an equivalent dose of LNPDTX-P. For the in vivo experiment, MIA PaCa-2 cells were implanted subcutaneously in NRG mice, and the mice were dosed with 2 mg/kg of GNPs and 6 mg/kg of DTX or an equivalent dose of LNPDTX-P. The results show that LNPDTX-P-treated tumour samples had double the amount GNPs compared to control samples, both in vitro and in vivo. The results are very promising, as LNPDTX-P have superior targeting of tumour tissues compared to free DTX due to their nanosize and their ability to be functionalized. Because of their minimal toxicity to normal tissues, both GNPs and LNPDTX-P could be ideal radiosensitization candidates in radiotherapy and would produce very promising synergistic therapeutic outcomes. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy)
►▼ Show Figures

Graphical abstract

14 pages, 2957 KiB  
Article
Theranostic Applications of an Ultra-Sensitive T1 and T2 Magnetic Resonance Contrast Agent Based on Cobalt Ferrite Spinel Nanoparticles
by Georgy Mikhaylov, Urska Mikac, Miha Butinar, Vito Turk, Boris Turk, Sergey Psakhie and Olga Vasiljeva
Cancers 2022, 14(16), 4026; https://doi.org/10.3390/cancers14164026 - 20 Aug 2022
Cited by 5 | Viewed by 1495
Abstract
Nano-dimensional materials have become a focus of multiple clinical applications due to their unique physicochemical properties. Magnetic nanoparticles represent an important class of nanomaterials that are widely studied for use as magnetic resonance (MR) contrast and drug delivery agents, especially as they can [...] Read more.
Nano-dimensional materials have become a focus of multiple clinical applications due to their unique physicochemical properties. Magnetic nanoparticles represent an important class of nanomaterials that are widely studied for use as magnetic resonance (MR) contrast and drug delivery agents, especially as they can be detected and manipulated remotely. Using magnetic cobalt ferrite spinel (MCFS) nanoparticles, this study was aimed at developing a multifunctional drug delivery platform with MRI capability for use in cancer treatment. We found that MCFS nanoparticles demonstrated outstanding properties for contrast MRI (r1 = 22.1 s–1mM–1 and r2 = 499 s–1mM–1) that enabled high-resolution T1- and T2-weighted MRI-based signal detection. Furthermore, MCFS nanoparticles were used for the development of a multifunctional targeted drug delivery platform for cancer treatment that is concurrently empowered with the MR contrast properties. Their therapeutic effect in systemic chemotherapy and unique MRI double-contrast properties were confirmed in vivo using a breast cancer mouse tumor model. Our study thus provides an empirical basis for the development of a novel multimodal composite drug delivery system for anticancer therapy combined with noninvasive MRI capability. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy)
►▼ Show Figures

Figure 1

16 pages, 4943 KiB  
Article
Encapsulation of Hydrophobic Porphyrins into Biocompatible Nanoparticles: An Easy Way to Benefit of Their Two-Photon Phototherapeutic Effect without Hydrophilic Functionalization
by Limiao Shi, Christophe Nguyen, Morgane Daurat, Nicolas Richy, Corentin Gauthier, Estelle Rebecq, Magali Gary-Bobo, Sandrine Cammas-Marion, Olivier Mongin, Christine O. Paul-Roth and Frédéric Paul
Cancers 2022, 14(10), 2358; https://doi.org/10.3390/cancers14102358 - 10 May 2022
Cited by 3 | Viewed by 1455
Abstract
Star-shaped hydrophobic porphyrins, acting as powerful fluorescent two-photon photosensitizers for oxygen in organic solvents, can easily be loaded into PMLABe polymeric nanoparticles at various concentrations. In this contribution, the performance of these porphyrin-containing nanoparticles in terms of photodynamic therapy (PDT) is compared to [...] Read more.
Star-shaped hydrophobic porphyrins, acting as powerful fluorescent two-photon photosensitizers for oxygen in organic solvents, can easily be loaded into PMLABe polymeric nanoparticles at various concentrations. In this contribution, the performance of these porphyrin-containing nanoparticles in terms of photodynamic therapy (PDT) is compared to those of the corresponding water-soluble porphyrin analogues when irradiated in MCF-7 cancer cells. While quite promising results are obtained for performing PDT with these nanoparticles, validating this approach as a mean for using more easily accessible and less expensive photosensitizers, from a synthetic perspective, we also show that their luminescence can still be used for bioimaging purposes in spite of their confinement in the nanoparticles, validating also the use of these nano-objects for theranostic purposes. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy)
►▼ Show Figures

Graphical abstract

10 pages, 2207 KiB  
Article
Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model
by Yuya Higashi, Shuji Ikeda, Kotaro Matsumoto, Shinsuke Satoh, Aoi Komatsu, Hiroshi Sugiyama and Fuyuhiko Tamanoi
Cancers 2022, 14(4), 951; https://doi.org/10.3390/cancers14040951 - 14 Feb 2022
Cited by 1 | Viewed by 2440
Abstract
Background: The KRAS inhibitor KR12, based on pyrrole-imidazole polyamide (PIP), has been developed and shown to exhibit efficacy in mouse experiments. Because some PIP species exhibit tumor accumulation capability, we decided to evaluate whether the PIP portion of KR12 exhibits tumor accumulation. We [...] Read more.
Background: The KRAS inhibitor KR12, based on pyrrole-imidazole polyamide (PIP), has been developed and shown to exhibit efficacy in mouse experiments. Because some PIP species exhibit tumor accumulation capability, we decided to evaluate whether the PIP portion of KR12 exhibits tumor accumulation. We employed the CAM assay that provides a simple method for tumor accumulation evaluation. Methods: KR12 PIP was synthesized and conjugated to TAMRA to produce a fluorescently labeled reagent (KR12-TAMRA). This reagent was injected into a fertilized chicken egg that has been transplanted with human cancer cells. Distribution of the red fluorescence was examined by cutting out tumor as well as various organs from the embryo. Results: The red fluorescence of KR12-TAMRA was found to overlap with the green fluorescence of the tumor formed with GFP-expressing cancer cells. We also observed nuclear localization of KR12-TAMRA. Treatment of KR12 that contained the alkylating agent CBI in the tumor-bearing chicken egg resulted in tumor growth inhibition. Conclusions: KR12 contains a PIP that has two key features: tumor accumulation and nuclear localization. KR12 conjugated with CBI exhibits inhibition of tumor growth in the CAM model. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 1466 KiB  
Review
Photochemical Internalization of siRNA for Cancer Therapy
by Lamiaa Mohamed Ahmed Ali and Magali Gary-Bobo
Cancers 2022, 14(15), 3597; https://doi.org/10.3390/cancers14153597 - 23 Jul 2022
Cited by 9 | Viewed by 1965
Abstract
In the race to design ever more effective therapy with ever more focused and controlled actions, nanomedicine and phototherapy seem to be two allies of choice. Indeed, the use of nanovectors making it possible to transport and protect genetic material is becoming increasingly [...] Read more.
In the race to design ever more effective therapy with ever more focused and controlled actions, nanomedicine and phototherapy seem to be two allies of choice. Indeed, the use of nanovectors making it possible to transport and protect genetic material is becoming increasingly important. In addition, the use of a method allowing the release of genetic material in a controlled way in space and time is also a strategy increasingly studied thanks to the use of lasers. In parallel, the use of interfering RNA and, more particularly, of small-interfering RNA (siRNA) has demonstrated significant potential for gene therapy. In this review, we focused on the design of the different nanovectors capable of transporting siRNAs and releasing them so that they can turn off the expression of deregulated genes in cancers through controlled photoexcitation with high precision. This mechanism, called photochemical internalization (PCI), corresponds to the lysosomal leakage of the cargo (siRNA in this case) after destabilization of the lysosomal membrane under light excitation. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy)
►▼ Show Figures

Figure 1

26 pages, 3023 KiB  
Review
Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue
by Muhammad Usman Munir
Cancers 2022, 14(12), 2904; https://doi.org/10.3390/cancers14122904 - 13 Jun 2022
Cited by 22 | Viewed by 3294
Abstract
Nanomedicine has been under investigation for several years to improve the efficiency of chemotherapeutics, having minimal pharmacological effects clinically. Ineffective tumor penetration is mediated by tumor environments, including limited vascular system, rising cancer cells, higher interstitial pressure, and extra-cellular matrix, among other things. [...] Read more.
Nanomedicine has been under investigation for several years to improve the efficiency of chemotherapeutics, having minimal pharmacological effects clinically. Ineffective tumor penetration is mediated by tumor environments, including limited vascular system, rising cancer cells, higher interstitial pressure, and extra-cellular matrix, among other things. Thus far, numerous methods to increase nanomedicine access to tumors have been described, including the manipulation of tumor micro-environments and the improvement of nanomedicine characteristics; however, such outdated approaches still have shortcomings. Multi-functional convertible nanocarriers have recently been developed as an innovative nanomedicine generation with excellent tumor infiltration abilities, such as tumor-penetrating peptide-mediated transcellular transport. The developments and limitations of nanomedicines, as well as expectations for better outcomes of tumor penetration, are discussed in this review. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy)
►▼ Show Figures

Figure 1

59 pages, 1639 KiB  
Review
Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy
by Valentina Foglizzo and Serena Marchiò
Cancers 2022, 14(10), 2473; https://doi.org/10.3390/cancers14102473 - 17 May 2022
Cited by 7 | Viewed by 3896
Abstract
Malignant tumors originate from a combination of genetic alterations, which induce activation of oncogenes and inactivation of oncosuppressor genes, ultimately resulting in uncontrolled growth and neoplastic transformation. Chemotherapy prevents the abnormal proliferation of cancer cells, but it also affects the entire cellular network [...] Read more.
Malignant tumors originate from a combination of genetic alterations, which induce activation of oncogenes and inactivation of oncosuppressor genes, ultimately resulting in uncontrolled growth and neoplastic transformation. Chemotherapy prevents the abnormal proliferation of cancer cells, but it also affects the entire cellular network in the human body with heavy side effects. For this reason, the ultimate aim of cancer therapy remains to selectively kill cancer cells while sparing their normal counterparts. Nanoparticle formulations have the potential to achieve this aim by providing optimized drug delivery to a pathological site with minimal accumulation in healthy tissues. In this review, we will first describe the characteristics of recently developed nanoparticles and how their physical properties and targeting functionalization are exploited depending on their therapeutic payload, route of delivery, and tumor type. Second, we will analyze how nanoparticles can overcome multidrug resistance based on their ability to combine different therapies and targeting moieties within a single formulation. Finally, we will discuss how the implementation of these strategies has led to the generation of nanoparticle-based cancer vaccines as cutting-edge instruments for cancer immunotherapy. Full article
(This article belongs to the Special Issue Nanoplatforms Based Cancers Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop